Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.

Published

Journal Article

The combination of cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate was used to treat 15 patients with recurrent and metastatic endometrial cancer. Four patients had a complete response and one patient had a partial response, yielding a total response rate of 33%. Five patients had stable disease. The median survival for the whole group was 38 weeks. The median survival for responders was 60 weeks, and that for nonresponders was 21 weeks. The median progression-free survival for the whole group was 17 weeks. The median progression-free survival for responders was 32 weeks, and that for patients with stable disease was 25 weeks. The toxic reactions noted were primarily nausea, vomiting, and myelosuppression. The combination of cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate has modest effectiveness in the treatment of metastatic or recurrent carcinoma of the endometrium.

Full Text

Duke Authors

Cited Authors

  • Hoffman, MS; Roberts, WS; Cavanagh, D; Praphat, H; Solomon, P; Lyman, GH

Published Date

  • October 1989

Published In

Volume / Issue

  • 35 / 1

Start / End Page

  • 75 - 77

PubMed ID

  • 2477317

Pubmed Central ID

  • 2477317

International Standard Serial Number (ISSN)

  • 0090-8258

Digital Object Identifier (DOI)

  • 10.1016/0090-8258(89)90016-4

Language

  • eng

Conference Location

  • United States